36 Year Member of the NYSE, Director of Trading Floor Operations, DME. Chairman at Wall Street Capital Partners, Veteran of Goldman Sachs and Partner in the largest EB5 project in USA. Former Board Director, Vision Finance, Largest Fund in Asia. Advisory Board: United Nations, MoMA Regular expert commentator on CNBC and all major networks, viewed by 350 million people per week around the globe.
Mr. Valdes attended Seton Hall, and graduated from NYU. He attended Harvard Business School.
Jack Quinn's career highlights include public service as Counsel to the President of the United States and other positions in the Executive and Legislative branches of Government; twenty years at Arnold & Porter, a leading law firm in the nation's capital; and the Chairmanship of a major public affairs firm that he has led for more than a dozen years.
Mr. Quinn served as Counsel to the Clinton-Gore Presidential Transition after the 1992 election. His first position in the Clinton-Gore Administration was serving as the Vice President's Counsel and Deputy Chief of Staff from January to June 1993. He then became Assistant to the President and Chief of Staff and Counselor to the Vice President in July 1993. In November 1995, Mr. Quinn was appointed Counsel to the President of the United States.
As White House Counsel, Mr. Quinn was the principal advisor to the President and senior White House officials on all legal aspects of policy and legislation before them. He also advised the President and Executive Branch officials on executive appointments and judicial nominations, issues of executive privilege and the powers of the presidency in general, litigation involving the President in his official capacity, financial disclosure requirements, conflicts of interest, separation the President's official and political activities, application of the War Powers Act and other requirements that may apply to the use of force or intelligence-gathering activities, as well as other issues of legal significance to the conduct of the presidency.
Mr. Quinn has served on a number of boards, including Fannie Mae (1997–2000) as a presidential appointee; the Philadelphia Stock Exchange (1997-1999) at the recommendation of the then-Chairman of the SEC; RepEquity (2012); the Robert F. Kennedy Memorial (1998-2005); and the Center City Consortium (2006-2010). He currently serves on the boards of Alternative Packaging Solutions (APS), and Academi, a private security and training enterprise that was purchased in 2010 from owners previously operating the company as Blackwater Worldwide. Mr. Quinn is one of two independent directors on Academi’s board who oversee the company’s governance and compliance activities and policies.
Mr. Norris co-founded the The Carlyle Group in 1987; Carlyle is a global private equity and investment firm with offices around the world. Mr Norris was a Managing Director of Carlyle until 1996 and served on the Boards of Directors of Carlyle portfolio companies. Prior to Carlyle, Mr. Norris was a Corporate Vice President of The Marriott Corporation, where he was a strategist and advisor for the company’s public and private financing and limited partnerships, and also head of the Tax department.
Mr. Norris possesses substantial experience in financing, providing strategic business advice to portfolio companies, analyzing and investing in public and private companies as well as serving on the board of directors of numerous companies. Mr Norris was appointed by President Bush, confirmed by the US Senate, and served on the board of the Federal Retirement Thrift Investment Board.
John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000.
John McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy.
At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.
Don Steinbrugge's achievements over his 30 year career in institutional investment management sales include serving as the head of sales for one of the world's largest hedge funds and institutional investment management firms; Don was a founding principal of Andor Capital Management, which was formed when he and a number of his associates spun out of Pequot Capital Management. At Andor he was Head of Sales, Marketing, and Client Service and was a member of the firm's Operating Committee. When he left Andor, the firm was ranked by assets under management as the 2nd largest hedge fund firm in a survey by Absolute Return Magazine. Prior to his stint at Pequot, Don was a Managing Director and Head of Institutional Sales for Merrill Lynch Investment Managers, which at the time was one of the largest investment managers in the world ranked by assets under management. Don was also Global Head of Institutional Sales and member of the executive committee for NationsBank Investment Management (now Bank of America Capital Management).
Don is a member of the Investment Committee for The City of Richmond Retirement System, a member of the Board of Directors for the Hedge Fund Association and a member of the Board of Directors of Lewis Ginter Botanical Gardens. In addition he is a former 2 term Board of Directors member the University of Richmond's Robins School of Business, The Science Museum of Virginia Endowment Fund, The Richmond Ballet (The State Ballet of Virginia) and the Richmond Sports Backers.￼￼￼￼￼￼￼￼￼￼